Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases

Status Recruiting

Clinical Trial Summary

The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.

Clinical Trial Description

Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00749697
Study type	Interventional
Source	Royal Marsden NHS Foundation Trust
Contact	Dr Kate Newbold
Phone	020 86613638
Email	kate.newbold@rmh.nhs.uk
Status	Recruiting
Phase	N/A
Start date	May 2008
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02658513` - Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
Withdrawn	`NCT01707056` - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma	N/A
Completed	`NCT00215605` - Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies	Phase 1
Completed	`NCT06439745` - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Terminated	`NCT04327999` - Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System	Phase 2
Completed	`NCT02194920` - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function	N/A
Enrolling by invitation	`NCT06095362` - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW	Phase 1
Not yet recruiting	`NCT05949424` - OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults	Phase 4
Active, not recruiting	`NCT02145143` - Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study	N/A
Terminated	`NCT01865838` - A Study Into the Effect of Seprafilm in Open Total Thyroidectomy	N/A
Enrolling by invitation	`NCT04411290` - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed	`NCT01813136` - Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma	Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Active, not recruiting	`NCT02185560` - Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Completed	`NCT04462471` - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Phase 1
Completed	`NCT01433809` - Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm	N/A
Recruiting	`NCT00929318` - Influence of Thyroid Hormones on the Woundhealing Process	N/A
Completed	`NCT05178186` - Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer	N/A
Completed	`NCT02773667` - Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
Completed	`NCT01013597` - Trial of LBH589 in Metastatic Thyroid Cancer	Phase 2